180 related articles for article (PubMed ID: 14691611)
1. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
[TBL] [Abstract][Full Text] [Related]
2. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
[TBL] [Abstract][Full Text] [Related]
3. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
[TBL] [Abstract][Full Text] [Related]
4. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
5. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
[TBL] [Abstract][Full Text] [Related]
6. Investigations of 99mTc morpholino pretargeting in mice.
Liu G; Liu C; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Nucl Med Commun; 2003 Jun; 24(6):697-705. PubMed ID: 12766607
[TBL] [Abstract][Full Text] [Related]
7. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.
He J; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich D
Mol Pharm; 2010 Aug; 7(4):1118-24. PubMed ID: 20507096
[TBL] [Abstract][Full Text] [Related]
8. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice.
Liu G; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Q J Nucl Med; 2002 Sep; 46(3):233-43. PubMed ID: 12134139
[TBL] [Abstract][Full Text] [Related]
9. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies.
He J; Liu G; Dou S; Gupta S; Rusckowski M; Hnatowich D
Bioconjug Chem; 2007; 18(3):983-8. PubMed ID: 17385902
[TBL] [Abstract][Full Text] [Related]
10. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ
Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
[TBL] [Abstract][Full Text] [Related]
11. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract][Full Text] [Related]
12. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
Liu G; Dou S; Pretorius PH; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):272-80. PubMed ID: 17909792
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.
Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837
[TBL] [Abstract][Full Text] [Related]
14. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications.
Mang'era KO; Liu G; Yi W; Zhang Y; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med; 2001 Nov; 28(11):1682-9. PubMed ID: 11702111
[TBL] [Abstract][Full Text] [Related]
15. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772
[TBL] [Abstract][Full Text] [Related]
16. A comparison of in vitro and in vivo stability in mice of two morpholino duplexes differing in chain length.
He J; Liu G; Zhang S; Vanderheyden JL; Liu N; Liu C; Zhang Y; Gupta S; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2003; 14(5):1018-23. PubMed ID: 13129406
[TBL] [Abstract][Full Text] [Related]
17. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
Liu CB; Liu GZ; Liu N; Zhang YM; He J; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
[TBL] [Abstract][Full Text] [Related]
19. Optical pretargeting of tumor with fluorescent MORF oligomers.
He J; Rusckowski M; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich DJ
Mol Imaging Biol; 2007; 9(1):17-23. PubMed ID: 17171474
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]